This article is sponsored by Standard BioTools. Neurodegenerative diseases affect more than 57 million people globally, a figure expected to double within two decades1,2. This alarming projection reflects three major clinical challenges: difficulty diagnosing disease in early, treatable stages; a lack of curative therapies; and limited treatment options2,3. Gradual onset, overlapping symptoms and biological heterogeneity […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!